Expression profiling reveals hepsin overexpression in prostate cancer.

Prostate cancer is the most commonly diagnosed noncutaneous cancer in men. Despite this fact, many of the genetic changes that coincide with prostate cancer progression remain enigmatic. We have addressed this problem by characterizing the expression profiles of several benign and malignant human prostate samples, and we have identified several genes that are differentially expressed between benign and malignant glands. One gene that was overexpressed encodes the serine protease hepsin. We used an independent sample set to confirm that hepsin is overexpressed in prostate tumors, and in situ hybridization demonstrates that hepsin is specifically overexpressed in the carcinoma cells themselves. These facts, together with the molecular properties of hepsin, make it an ideal target for prostate cancer therapy.

[1]  A. Ullrich,et al.  Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways. , 1986, Science.

[2]  H. Ploegh,et al.  Purification, cDNA‐cloning and expression of human diacylglycerol kinase , 1990, FEBS letters.

[3]  K. Kurachi,et al.  Hepsin, a cell membrane-associated protease. Characterization, tissue distribution, and gene localization. , 1991, The Journal of biological chemistry.

[4]  M. Simon,et al.  Gα15 and Gα16 Couple a Wide Variety of Receptors to Phospholipase C (*) , 1995, The Journal of Biological Chemistry.

[5]  V. Koteliansky,et al.  A novel dystrophin/utrophin-associated protein is an enzymatically inactive member of the phosphoglucomutase superfamily. , 1996, European journal of biochemistry.

[6]  K. Shigemasa,et al.  Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. , 1997, Cancer Research.

[7]  M. Halks-Miller,et al.  Generation and characterization of mice deficient in hepsin, a hepatic transmembrane serine protease. , 1998, The Journal of clinical investigation.

[8]  W. Wahli,et al.  A Simplified In Situ Hybridization Protocol Using Non-radioactively Labeled Probes to Detect Abundant and Rare mRNAs on Tissue Sections , 1998 .

[9]  W. Kisiel,et al.  Expression of the Factor VII Activating Protease, Hepsin, in situ in Renal Cell Carcinoma , 1998, Thrombosis and Haemostasis.

[10]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[11]  Mark A. Watson,et al.  EGR1 Target Genes in Prostate Carcinoma Cells Identified by Microarray Analysis* , 2000, The Journal of Biological Chemistry.

[12]  W. Dai,et al.  Transforming activity of receptor tyrosine kinase tyro3 is mediated, at least in part, by the PI3 kinase-signaling pathway. , 2000, Blood.

[13]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[14]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[15]  M. Shen,et al.  Molecular genetics of prostate cancer. , 2000, Genes & development.

[16]  J. Morser,et al.  Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. Pandolfi,et al.  Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse , 2001, Nature Genetics.

[18]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[19]  U. Alon,et al.  Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. , 2001, Cancer research.

[20]  M. Watson,et al.  Advances in Brief Gene Expression Profiling with Oligonucleotide Microarrays Distinguishes World Health Organization Grade of Oligodendrogliomas 1 , 2001 .